Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.81 |
| ▸ | ADRB1 | P08588 | 19/20 | 0.81 |
| ▸ | ADRB3 | P13945 | 19/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | HTR1A | P08908 | 3/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.74 |
| ▸ | HTR1B | P28222 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
| ▸ | DRD4 | P21917 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | FPR3 | P25089 | 1/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | GPR183 | P32249 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939190 | 1.00 | ADRB2 (0.81) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4808459 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4808449 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4629384 | 0.88 | ADRB2 (0.63) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| Acetic Acid SCHEMBL4810795 | 0.86 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4628373 | 0.86 | ADRB2 (0.92) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL144536 | 0.85 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4627326 | 0.85 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL118150 | 0.85 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL29798973 | 0.85 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556342-B1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-03-26 | — | — | EP | claimed |
| EP-2875020-B1 | PROCESS FOR THE PREPARATION OF A FUMARIC ACID SALT OF 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY- CHINAZOLIN-6-YLOXY]-1,4-DIAZA-SPIRO[5.5]UNDECAN-5-ONE | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| CN-105611929-A | PI3K Inhibitors for the Treatment of Respiratory Diseases | GLAXOSMITHKLINE IP DEV CO LTD | 2016-05-25 | — | — | CN | disclosed |
| US-9309228-B2 | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as a medicament and the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-8937073-B2 | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20140371226-A1 | 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY-QUINAZOLINE-6-YLOXY]-1,4-DIAZA-SPIRO[5.5]UNDECANE-5-ONE DIMALEATE, USE THEREOF AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| US-8906931-B1 | 9-[4-(3-chloro-2-fluoro-phenylamino-7-methoxy-quinazoline-6-yloxy]-1,4-diaza-spiro[5.5]undecane-5-one dimaleate, use thereof as a medicament and method for the production thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8901127-B2 | Pyridazin derivatives as antagonists of the bradykinin B1 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-02 | — | — | US | disclosed |
| US-8853225-B2 | 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazoline-6-yloxy]-1,4-diaza-spiro[5.5] undecane-5-one dimaleate, use thereof as a medicament and method for the production thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-8372838-B2 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| US-20130030003-A1 | 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY-QUINAZOLINE-6-YLOXY]-1,4-DIAZA-SPIRO[5.5]UNDECANE-5-ONE DIMALEATE, USE THEREOF AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20120208823-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120046284-A1 | Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| CN-101528290-A | Actuator for an inhaler | GLAXO GROUP LTD (GB) | 2009-09-09 | — | — | CN | disclosed |
| EP-1928654-A2 | LID SHEET FOR USE IN A BLISTER PACK | GLAXO GROUP LIMITED (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038488-A2 | LID SHEET FOR USE IN A BLISTER PACK | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | ADRB2 60/4885ADRB1 21/4885ADRB3 111/4885 |
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | ADRB2 484/4885ADRB1 275/4885ADRB3 276/4885 |
| US-20130030003-A1 | 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY-QUINAZOLINE-6-YLOXY]-1,4-DIAZA-SPIRO[5.5]UNDECANE-5-ONE DIMALEATE, USE THEREOF AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF | GRK5, KLK3, GRK3 | ADRB2 37/4885ADRB1 10/4885ADRB3 9/4885 |
| US-20140371226-A1 | 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY-QUINAZOLINE-6-YLOXY]-1,4-DIAZA-SPIRO[5.5]UNDECANE-5-ONE DIMALEATE, USE THEREOF AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF | GRK5, KLK3, GRK3 | ADRB2 37/4885ADRB1 10/4885ADRB3 9/4885 |
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BDKRB1, BDKRB2, HRH2 | ADRB2 19/4885ADRB1 10/4885ADRB3 71/4885 |
| US-20120046284-A1 | Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof | CSNK1D, CSNK1A1, CSNK1A1L | ADRB2 43/4885ADRB1 31/4885ADRB3 84/4885 |
| US-20120208823-A1 | New Compounds | ABCG2, SDHA, UGT2B7 | ADRB2 1988/4885ADRB1 2539/4885ADRB3 1920/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | ADRB2 484/4885ADRB1 275/4885ADRB3 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.